Effects of nicotine on 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced depression of striatal dopamine content and spontaneous locomotor activity in C57 black mice

Pharmacological Research

Volumn 38, Issue 2, 1998, Pages 101-106

  Gao, Z G ^a   Cui, W Y ^a   Zhang, H T ^a   Liu, C G ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Dopamine; Locomotor activity; MPTP; Nicotine; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; NEUROTOXIN; NICOTINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; LOCOMOTION; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032146120     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1998.0337     Document Type: Article

References (33)

1. 1. Baron JA. Cigarette smoking and Parkinson's disease. Neurology 1986; 36: 1490-6.
2. 2. Baumann RJ, Jameson HD, McKean HD, Haack DG, Weisberg LM. Cigarette smoking and Parkinson's disease: a comparison of cases with matched neighbors. Neurology 1980; 30: 839-43.
3. 3. Godwin-Austen RB, Lee PN, Marmot MG, Stem GM. Smoking and Parkinson's disease. J Neurol Neurosurg Psychiatry 1982; 45: 577-81.
4. 4. Moll H. The treatment of post-encephalitic parkinsonism by nicotine. Br Med J 1926; 1: 1079-81.
5. 5. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine analog synthesis. Science 1983; 219: 979-80.
6. 6. Arai N, Misugi K, Goshima Y, Misu Y. Evaluation of a 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism. Brain Res 1990; 515: 57-63.
7. 7. Fredriksson A, Archer T. MPTP-induced behavioural and biochemical deficits: a parametric analysis. J Neural Transm 1994; 7: 123-32.
8. 8. Janson AM, Fuxe K, Sundstrom E, Agnati LF, Goldstein M. Chronic nicotine treatment partly protects against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of nigrostriatal dopamine neurons in the black mice. Acta Physiol Scand 1988; 132: 589-91.
9. 9. Gao ZG, Cui WY, Liu CG. Modulation of apomorphine induced rotations in unilaterally hydroxydopamine-lesioned rats by cholinergic agonists and antagonists. Life Sci 1997; 60: PL317-23.
10. 3H]dopamine from rat striatal synaptosomes. Neurosci Lett 1995; 189: 171-5.
11. 11. Reith MEA, Meisler BE, Lajtha A. Locomotor effects of cocaine, cocaine congeners, and local anaesthetics in mice. Pharmacol Biochem Behav 1985; 23: 831-6.
12. 1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: an immunohistochemistry study. Brain Res 1989; 484: 297-303.
13. 13. Friedriksson A, Plaznik A, Sundstrom E, Jonsson G, Archer T. MPTP-induced hypoactivity in mice: reversal by L-dopa. Pharmacol Toxicol 1990; 67: 295-301.
14. 14. Hu SC, Chang FW, Sung YJ, Hsu WM, Lee NH. Neurotoxic effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in substantia nigra and locus coeruleus in BALB/c mice. J Pharmacol Exp Ther 1991; 259: 1379-87.
15. 15. Sundstrom E, Fredriksson A, Archer T. Chronic neurochemical and behavioural changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease. Brain Res 1990; 528: 181-8.
16. 16. Weihmuller FB, Hadjiconstantinou M, Bruno JP. Dopamine receptors and sensorimotor behaviour in MPTP-treated mice. Behav Brain Res 1990; 28: 263-73.
17. 1 ganglioside restores striatal dopamine and the 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-treated mouse. J Neurochem 1988; 51: 1190-6.
18. 18. Hefti F, Eng A, Melamed E. Partial lesions of the nigrostriatal pathway in the rat. Neuropharmacology 1985; 24: 19-25.
19. 19. Jovoy-Agid F, Ruberg M, Taquet H, Bokobza B, Agid Y, Gaspar P, Berger B, N'Guyen-Legros J, Alvarez C, Gray F, Escourolle R, Scatton B, Rouguier L. Biochemical neuropathology of Parkinson's disease. Adv Neurol 1984; 40: 189-98.
20. 20. Sershen H, Mason MF, Hashim A, Lajtha A. Effect of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on age-related changes in dopamine turnover and transporter function in the mouse striatum. Eur J Pharmacol 1985; 113: 135-6.
21. 21. Fuxe K, Janson AM, Janson A, Andersson K, Eneroth P, Agnati LF. Chronic nicotine treatment increases dopamine levels and reduces dopamine utilization in substantia nigra and in surviving forebrain dopamine nerve terminal systems after partial dimesencephalic hemitransection. Nauny-Schmiedeberg's Arch Pharmacol 1990; 341: 171-81.
22. 22. Marks MJ, Burch JB, Collins AC. Effects of chronic nicotine infusion on tolerance development and nicotine receptors. J Pharmacol Exp Ther 1983; 226: 817-25.
23. 23. Janson AM, Fuxe K, Agnati LF, Kitayama L, Harfstrand A, Andersson K, Goldstein M. Chronic nicotine treatment counteracts the disappearance of tyrosine-hydroxylase-immunoreactive nerve cell bodies, dendrites and terminals in mesostriatal dopainine system of male rat after partial hemitransaction. Brain Res 1988; 455: 332-45.
24. 24. Grenhoff J, Janson AM, Svensson TH, Fuxe K. Chronic continuous nicotine treatment causes decreased burst firing of nigral dopamine neurons in rats partially hemitransected at the meso-diencephalic junction. Brain Res 1991; 562: 347-51.
25. 25. Heidmann T, Bemhart J, Neumann E, Changeux JP. Rapid kinetics of agonist binding and permeability response analyzed in parallel on acetylcholine receptor rich membranes from Torpedo Marmorata Biochem 1983; 22: 5452-9.
26. 26. Changeux JP. The Tips lecture. The nicotinic acetylcholine receptor: an allosteric protein prototype of ligand-gated ion channels. Trends Pharmacol Sci 1990; 11: 485-92.
27. 27. Noronha-Blob L, Gover R, Baumgold J. Calcium influx mediated by nicotinic receptors and voltage gated calcium channels in SK-N-SH human neuroblastoma cells. Biochem Biophys Res Commun 1989; 162: 1230-5.
28. 28. Schuller HM, Nvlen E, Park P, Becker KL. Nicotine, acetylcholine and bombesin are trophic growth factors in neuroendocrine cell lines derived from experimental hamster lung tumors. Life Sci 1990; 47: 571-8.
29. 29. Rosecrans JA, Villanueva HF. Discrimination stimulus properties of nicotine: mechanisms of transduction. NIDA Res Monogr 1991; 116: 101-16.
30. 30. Behmand RA, Harik SI. Nicotine enhances 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine neurotoxicity. J Neurochem 1992; 58: 776-9.
31. 31. Hadjiconstantinou M, Hubble JB, Weimlinger TA, Neff NH. Enhanced-MPTP neurotoxicity after treatment with isoflurophate or cholinergic agonists. J Pharmacol Exp Ther 1994; 270: 639-44.
32. 32. Janson AM, Fuxe K, Goldstein M. Differential effects of acute and chronic nicotine treatment on MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced degeneration of nigrostriatal dopamine neurons in the black mouse. Clin Invest 1992; 70: 232-8.
33. + levels do not necessarily correlate with striatal dopamine levels after MPTP treatment in mice. Neurodegeneration 1996; 5: 129-36.